Please login to the form below

Not currently logged in
Email:
Password:

Takeda's diabetes drug enters phase III

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development

Takeda Pharmaceutical's TAK-875, a novel investigational therapy for diabetes, has entered phase III development.

TAK-875 is being investigated for its ability as an agonist of GPR40, a receptor in pancreatic islet cells, with Takeda hoping it can selectively improve glucose-dependent insulin secretion with a potential for reduced risk of hypoglycaemia.

It is the first such drug to reach the phase III stage of development.

Dr Thomas Strack, vice president, clinical science, Takeda Global Research & Development Center, US, said: "Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals."

The first phase III trial in the US/Europe programme will enrol about 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise. The study's primary endpoint will be the change in blood glucose levels at week 24.

19th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...
Ingrid
30 Women Leaders in UK Healthcare (part 2)
Part two of our list of thirty women leaders 11-20...

Infographics